MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement

MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement

Submitted by admin on April 15, 2024 - 11:20am
Source: 
Clinical Trials Arena
News Tags: 
MaaT Pharma
MaaT013
graft vs host disease
clinical trials
Headline: 
MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement
snippet: 

Lyon, France-based MaaT Pharma has announced positive 18-month data for its lead candidate MaaT013 showing an overall survival advantage in acute graft versus host disease (aGvHD).

Do Not Allow Advertisers to Use My Personal information